Ontology highlight
ABSTRACT:
SUBMITTER: Martin del Campo SE
PROVIDER: S-EPMC4546911 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature
Martin del Campo Sara E SE Levine Kala M KM Mundy-Bosse Bethany L BL Grignol Valerie P VP Fairchild Ene T ET Campbell Amanda R AR Trikha Prashant P Mace Thomas A TA Paul Bonnie K BK Jaime-Ramirez Alena Cristina AC Markowitz Joseph J Kondadasula Sri Vidya SV Guenterberg Kristan D KD McClory Susan S Karpa Volodymyr I VI Pan Xueliang X Olencki Thomas E TE Monk J Paul JP Mortazavi Amir A Tridandapani Susheela S Lesinski Gregory B GB Byrd John C JC Caligiuri Michael A MA Shah Manisha H MH Carson William E WE
Journal of immunology (Baltimore, Md. : 1950) 20150803 5
Sorafenib is an oral multikinase inhibitor that was originally developed as a Raf kinase inhibitor. We hypothesized that sorafenib would also have inhibitory effects on cytokine signaling pathways in immune cells. PBMCs from normal donors were treated with varying concentrations of sorafenib and stimulated with IFN-α or IL-2. Phosphorylation of STAT1 and STAT5 was measured by flow cytometry and confirmed by immunoblot analysis. Changes in IFN-α- and IL-2-stimulated gene expression were measured ...[more]